US FDA gives Fast Tack Designation to Eli Lilly’s Tirzepatide to Treat Adults with Obesity
Eli Lilly and Company received Fast Track designation from the US Food and Drug Administration (FDA) for tirzepatide to treat adults with obesity or weight-related comorbidities. The US FDA grants Fast Track designation to facilitate development and expedite the review of medicines used for the treatment of serious conditions or diseases and to fulfil unmet […]
Continue Reading